Emmaus Life Sciences, Inc.
EMMAW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.04M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.04 Million |
|---|---|
| Enterprise Value | $31.76 Million |
| Earnings per Share | $-0.12 |
| Beta | 0 |
| Outstanding Shares | 70,188,263 |
Return
| Return on Equity | 9.10% |
|---|---|
| Return on Assets | -36.80% |
| Return on Invested Capital | -6.71% |
Valuation & Multiples
| P/E Ratio | -0.61 |
|---|---|
| PEG | 0.28 |
| Price to Sales | - |
| Price to Book Ratio | -0.07 |
| Enterprise Value to Revenue | 2.04 |
| Enterprise Value to EBIT | 9.51 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.96 |
| Debt to Equity | -0.46 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Emmaus Life Sciences, Inc.
33 employees
CEO: Willis C. Lee
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the Unit...